534 Results for "

AML

" in MedChemExpress (MCE) Product Catalog:
Products (534)

534 Results for "AML" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-112041
CAS No.: 1610964-64-1
Purity:  99.45%
Synonyms: PTC596
Target:  

BMI1 Apoptosis

Research Areas:  

Cancer

Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B1336
CAS No.: 67-45-8
Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114226
CAS No.: 1887014-12-1
Purity:  99.16%
Synonyms: FT-2102
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-160415
CAS No.: 3066823-45-5
Target:  

PROTACs METTL3 Apoptosis

Research Areas:  

Cancer

WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m 6A modification and proliferation of AML cells, and induces apoptosis.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-160415A
Target:  

PROTACs METTL3 Apoptosis

Research Areas:  

Cancer

WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-153604
CAS No.: 3034769-78-0
Purity:  98.68%
Research Areas:  

Cancer

MC4171 (compound 34) is a selective KAT8 inhibitor (IC50=8.1 µM). MC4171 has been shown to exhibit moderate micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, with potential for studying cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109539
CAS No.: 220578-59-6
Purity:  98.0%
Research Areas:  

Cancer

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13680
CAS No.: 97207-47-1
Purity:  99.91%
Synonyms: Dian III; N-Methylisoindigotin; Natura-α
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12333
CAS No.: 1457983-28-6
Purity:  ≥98.0%
Synonyms: G-749
Target:  

FLT3 Apoptosis

Research Areas:  

Cancer

Denfivontinib (G-749) is a potent, oral active and ATP competitive FLT3 inhibitor, with IC50s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112376
CAS No.: 2010159-47-2
Purity:  98.16%
Research Areas:  

Cancer

MZP-54 is a PROTAC degrader that selectively targets BRD3/BRD4, with a DC50 of < 0.05 μM in AML cells. MZP-54 recruits VHL to form a ternary complex, induces BRD3/BRD4 degradation via the ubiquitin-proteasome pathway, inhibits c-Myc expression, and exerts antiproliferative activity. MZP-54 can be used for the research of acute myeloid leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16172
CAS No.: 791595-09-0
Synonyms: Dimethylamino Parthenolide
Target:  

NF-κB

Research Areas:  

Cancer

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148669
CAS No.: 2654081-35-1
Purity:  99.05%
Synonyms: JNJ-75276617; Menin-MLL inhibitor 24
Research Areas:  

Cancer

Bleximenib (JNJ-75276617) is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-30272
CAS No.: 103-16-2
Target:  

Hapten

Research Areas:  

Cancer

Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and exhibits good potential for vitiligo research. Monobenzone is a potent inhibitor of RNR (Ribonucleotide reductase) enzyme activity by targeting RRM2 (a regulatory small subunit M2 of RNR) protein, and thus has significant anti-leukemia efficacy in vitro and in vivo. Monobenzone inhibits acute myeloid leukemia (AML) cells proliferation and DNA synthesis, induces cell cycle arrest, and Apoptosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10943
CAS No.: 839706-07-9
Purity:  99.70%
Target:  

Bcr-Abl Ack1

Research Areas:  

Cancer

GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-Abl WT and Bcr-Abl T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-129079A
CAS No.: 1445703-64-9
Purity:  99.79%
Research Areas:  

Endocrinology Cancer

TFMB-(S)-2-HG is a potent TET2 inhibitor. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG downregulates Wnt3a, β-catenin (intranuclear) protein expression. TFMB-(S)-2-HG inhibits osteogenic differentiation of cells. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144433
CAS No.: 1403598-56-0
Purity:  99.94%
Target:  

DNA Methyltransferase

Research Areas:  

Infection

DNMT3A-IN-1 (compound 1) is an effective and selective DNMT3A inhibitor. DNMT3A-IN-1 exhibits inhibitory activity against DNMT3A, with KI values ranging from 9.16 to 18.85 μM (AdoMet) and 11.37 to 23.34 μM (poly dI-dC). DNMT3A-IN-1 can induce apoptosis in acute myeloid leukemia (AML) cell lines (Apoptosis) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12445
CAS No.: 1421693-22-2
Purity:  99.18%
Synonyms: CDKI-73; LS-007
Target:  

CDK Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with Ki values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-123054
CAS No.: 314761-14-3
Purity:  99.49%
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

BTSA1 is a potent, high affinity and orally active BAX activator with an IC50 of 250 nM and an EC50 of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-128724
CAS No.: 1863952-15-1
Purity:  99.58%
Target:  

p97

Research Areas:  

Cancer

CB-5339 is an oral activity potent p97 inhibitor with an IC50 <30 nM. CB-5339 can be used for leukemia research . CB-5339 extracted from WO2015109285A1 compound FF07.
loading...
    loading...